LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 833-844

  Yan, S Betty ^a   Peek, Victoria L ^a   Ajamie, Rose ^a   Buchanan, Sean G ^a   Graff, Jeremy R ^a   Heidler, Steven A ^a   Hui, Yu Hua ^a   Huss, Karen L ^a   Konicek, Bruce W ^a   Manro, Jason R ^a   Shih, Chuan ^a   Stewart, Julie A ^a   Stewart, Trent R ^a   Stout, Stephanie L ^a   Uhlik, Mark T ^a   Um, Suzane L ^a   Wang, Yong ^a   Wu, Wenjuan ^a   Yan, Lei ^a   Yang, Wei J ^a   Zhong, Boyu ^a   Walgren, Richard A ^a   more..

^a ELI LILLY AND COMPANY   (United States)

Author keywords

LY2801653; MET inhibitor; MKNK; MST1R; ROS1

Indexed keywords

ANTINEOPLASTIC AGENT; AXL KINASE; CD135 ANTIGEN; DDR1 KINASE; DDR2 KINASE; GLUCOSE TRANSPORTER 1; LY 2801653; MERTK KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MKNK1 KINASE; MKNK2 KINASE; MST1R KINASE; N [3 FLUORO 4 [[1 METHYL 6 (1H PYRAZOL 4 YL) 1H INDAZOL 5 YL]OXY]PHENYL] 1 (4 FLUOROPHENYL) 6 METHYL 2 OXO 1,2 DIHYDROPYRIDINE 3 CARBOXAMIDE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; ROS1 KINASE; SCATTER FACTOR RECEPTOR; TEK KINASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MEAN RESIDENCE TIME; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BLOOD VESSELS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INDAZOLES; MICE; MUTATION; NIACINAMIDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; TETRAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880924426     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9912-9     Document Type: Article

References (39)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-25
2. Comoglio PM, Giordano A, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Disc 7:504-16
3. Turke AB, Zejnullahum K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al (2010) Preexistence and clonal selection of Met amplification in EGFR mutant NSCLC. Cancer Cell 17:77-88
4. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K et al (2011) Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thoracic Oncol 7:272-80
5. Bean J, Brennan C, Shih JY, Riely GJ, Viale A, Wang L et al (2007) Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Nat'l Acad Sci USA 104:20932-7
6. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007) Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-43
7. Benvenuti S, Lazzari L, Arnesano A, Chiavi GL, Gentile A, Comoglio PM (2011) RON kinase trans-phosphorylation sustains MET oncogene addition. Cancer Res 71:1945-55
8. Yeh CY, Shih SM, Yeh HH, Wu TJ, Shin JW, Chang TY et al (2011) Transcriptional activation of the Axl and PDGFR-alpha by cMet through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 11:139
9. Li T, Pobanz MA, Shih C, Wu Z, Yang WJ, Zhong B (2011) Amidophenoxyindazoles useful as inhibitors of c-Met. US 8030302B2
10. Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, Zhang C et al (2006) Structural characterization of autoinhibited c-MET kinase produced by coexpression in bacteria with phosphatase. Proc Nat'l Acad Sci USA 103:3563-8
11. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Cryst Section D D60:2126-32
12. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst Section D D53:240-55
13. Rong S, Oskarsson M, Faletto D, Tsarfaty I, Resau JH, Nakamura T et al (1993) Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ 4:563-9
14. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude GF (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Nat'l Acad Sci USA 84:6379-83
15. Aarts LH, Roovers O, Ward AC, Touw IP (2004) Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics. Blood 103:571-9
16. Meier T, Uhlik MT, Chintharlapalli S, Dowless M, Van Horn R, Stewart J et al (2011) Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther 10:2168-78
17. Underiner TL, Herbertz T, Miknyoczki SJ (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anti-cancer agents Med Chem 10:7-27
18. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude GF (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89-103
19. Wang MH, Kurtz AL, Chen YQ (2000) Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21:1507-12
20. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG (2003) Flt3 mutations in acute myeloid leukemia cell lines. Leukemia 17:120-4
21. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73
22. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, De Stefani A et al (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547-55
23. Sattler M, Hasina R, Reddy MM, Gangadhar T, Salgia R (2011) The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3:171-84
24. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430:425-37
25. Jauch R, Cho MK, Jakel S, Netter C, Schreiter K, Aicher B et al (2006) Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment. EMBO J 25:4020-32
26. Jauch R, Jäkel S, Netter C, Schreiter K, Aicher B, Jäckle H et al (2005) Crystal structures of the Mnk2 kinase domain reveal an Inhibitory conformation and a zinc binding site. Structure 13:1559-68
27. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852-60
28. DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D (2006) Regulation of sprouty stability by Mnk-1-dependent phosphorylation. Mol Cell Biol 26:1898-907
29. Ueda T, Sasaki M, Elia AJ, Chio LIC, Hamada K, Fukunaga R et al (2010) Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Nat'l Acad Sci USA 107:13984-90
30. El-Deeb IM, Yoo KH, Lee SH (2010) ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev. doi: 10.1002/med.20206:1-25
31. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-203
32. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V et al (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6:e15640
33. Bergethon K, Shaw AT, Ou SHI, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-70
34. Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M et al (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72:2501-11
35. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Dis 1:78-89
36. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
37. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TPD (2003) Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23:69-75
38. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S (2011) Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10:1763-73
39. Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10:575-85